According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen‘s Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of the company’s outstanding stock. Gemphire Therapeutics represents a new addition to Cormorant Asset Management’s portfolio.
Gemphire Therapeutics is a clinical-stage biopharmaceutical company engaged in discovering and producing therapeutics to help treat people suffering from dyslipidemia. The company started trading on August 8 and since then its stock has gained 8.7%.
RAJ CREATIONZS / shutterstock.com
There are no other funds in our database with a known long position in Gemphire Therapeutics Inc. (NASDAQ:GEMP) at this time.
Follow Metavia Inc. (NASDAQ:MTVA)
Follow Metavia Inc. (NASDAQ:MTVA)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Cormorant Global Healthcare Master Fund | 0 | 748,350 | 0 | 748,350 | 748,350 | 8.1% |
| Cormorant Global Healthcare GP | 0 | 748,350 | 0 | 748,350 | 748,350 | 8.1% |
| Cormorant Asset Management | 0 | 900,000 | 0 | 900,000 | 900,000 | 9.7% |
| Bihua Chen | 0 | 900,000 | 0 | 900,000 | 900,000 | 9.7% |
Follow Bihua Chen's Cormorant Asset Management
Page 1 of 8 – SEC Filing
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | ||
| SCHEDULE 13G | ||
| Under the Securities Exchange Act of 1934 | ||
| (Amendment No. ___)* |
| Gemphire Therapeutics Inc. | ||
| (Name of Issuer) |
| Common Stock, par value $0.001 per share | ||
| (Title of Class of Securities) |
| 36870A108 | ||
| (CUSIP Number) |
| August 5, 2016 | ||
| (Date of Event which Requires Filing of this Statement) |
